Clinical Trials Logo
  1. Home
  2. Neuromuscular Disease
  3. NCT01074359

Safety and Efficacy Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation

Neuromuscular Disease Clinical Trial

Official title:
A Phase 2a, Double Blind, Randomized, Placebo-controlled, 28 Day, Two-arm, Parallel Group Study of A0001 in Patients With the A3243G Mitochondrial DNA Point Mutation and Evidence of Impaired Mitochondrial Function

Clinical Trial Summary

This is a phase 2a, double-blind, placebo-controlled, single-center study. Twenty-one patients who qualify for the study will be randomly assigned to either active drug or placebo. The study will take place at Newcastle University. Patients will have a 66% chance of getting active drug. Patients will be required to take study treatment orally twice a day for 28 days. A baseline visit will occur within 21 days of screening visit. All patients will be followed for 1 week after completion of study or early withdrawal from the study.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01074359
Study type Interventional
Source Penwest Pharmaceuticals Co.
Contact
Status Terminated
Phase Phase 2
Start date February 2010
Completion date November 2010
View Details
See also
  Status Clinical Trial Phase
Completed NCT02847299 - Comparison of a Hyperinflation Mode and Air Stacking on Neuromuscular Patients Under Volumetric Ventilation N/A
Completed NCT02551406 - Prognostic Value of Residual Hypoventilation in Mechanically Ventilated Neuromuscular Patients N/A
Completed NCT00860951 - P300 Brain Computer Interface Keyboard to Operate Assistive Technology Phase 1/Phase 2
Recruiting NCT02288299 - Long-Term Effect of LIAM on Respiratory Performance in NIV Patients Suffering From Neuromuscular Disease N/A
Completed NCT02284022 - Clinical Validation Protocol for BCI for the Communication of Patients Suffering From Neuromuscular Disorders. N/A
Completed NCT00001201 - Evaluation of Neuromuscular Disease N/A
Completed NCT00252252 - AutoVPAP Versus VPAP; Assessment of Sleep and Ventilation Phase 1
Completed NCT02153970 - Calibration and Validation of the PROMIS and Neuro-QOL Questionnaires in Cerebral Palsy and Congenital Muscular Dystrophy
Terminated NCT02317042 - Juno Perth Clinical Trial N/A
Terminated NCT02022072 - Evaluation of Vital Capacity Phase 2
Recruiting NCT04417023 - B3 for NMD: Bench to Bedside and Back
Recruiting NCT02532244 - Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases
Completed NCT01621984 - Therapeutic Riding and Neuromuscular Disease Phase 1
Recruiting NCT01900132 - Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteers N/A
Completed NCT00017745 - Phenotype/Genotype Correlations in Neuromuscular Disorders N/A
Recruiting NCT01560741 - Telemedicine and Ventilator Titration in Chronic Respiratory Patients Initiating Non-invasive Ventilation Phase 1
Completed NCT01644162 - Ventilator Monitoring in Early Exacerbation Detection N/A
Completed NCT00695591 - Home Sleep Testing in Neuromuscular Disease Patients N/A
Completed NCT01611597 - Continuous Measurement of the Activity for Clinical Evaluation at Home, for Non-ambulant Neuromuscular Patients N/A
Completed NCT01518439 - Instrumental and Manual Increase of Couch in Neuromuscular Patients N/A